Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Belite Bio (NASDAQ:BLTE – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Dermata Therapeutics and Belite Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -127.91% | -105.05% |
| Belite Bio | N/A | -13.14% | -12.88% |
Earnings & Valuation
This table compares Dermata Therapeutics and Belite Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($5.31) | -0.24 |
| Belite Bio | N/A | N/A | -$77.61 million | ($2.53) | -54.27 |
Belite Bio is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Dermata Therapeutics and Belite Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Belite Bio | 1 | 1 | 6 | 0 | 2.63 |
Dermata Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 693.65%. Belite Bio has a consensus price target of $203.80, indicating a potential upside of 48.43%. Given Dermata Therapeutics’ higher possible upside, equities research analysts clearly believe Dermata Therapeutics is more favorable than Belite Bio.
Risk & Volatility
Dermata Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.
Insider and Institutional Ownership
8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Dermata Therapeutics beats Belite Bio on 6 of the 11 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
